Anti-Alpha-synuclein antibody [syn204] (ab3309)
![Immunocytochemistry - Anti-Alpha-synuclein antibody [syn204] (ab3309)](https://www.abcam.com/ps/products/3/ab3309/Images/ab3309-2-anti-Alpha-synuclein-antibody-syn204-immunocytochemistry-immunofluorescence-Hap1-human.jpg "Immunocytochemistry - Anti-Alpha-synuclein antibody [syn204] (ab3309)")
Key features and details
- Mouse monoclonal [syn204] to Alpha-synuclein
- Suitable for: ICC
- Knockout validated
- Reacts with: Human
- Isotype: IgG2a
Overview
-
Product name
Anti-Alpha-synuclein antibody [syn204]
See all Alpha-synuclein primary antibodies -
Description
Mouse monoclonal [syn204] to Alpha-synuclein -
Host species
Mouse -
Specificity
Due to sequence homology ab3309 might react with Beta synuclein -
Tested Applications & Species
See all applications and species dataApplication Species WB Human
-
Immunogen
Recombinant full length protein (Human).
-
Positive control
- ICC: HAP1 cells.
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing the problem with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation.
One factor contributing to the crisis is the use of antibodies that are not suitable. This can lead to misleading results and the use of incorrect data informing project assumptions and direction. To help address this challenge, we have introduced an application and species grid on our primary antibody datasheets to make it easy to simplify identification of the right antibody for your needs.
Learn more here.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Store at -20°C or -80°C. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.40
Preservative: 0.1% Sodium azide
Constituent: PBS -
Concentration information loading... -
Purity
Protein G purified -
Clonality
Monoclonal -
Clone number
syn204 -
Isotype
IgG2a -
Light chain type
kappa -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab3309 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Guaranteed
Tested applications are guaranteed to work and covered by our Abpromise guarantee.
Predicted
Predicted to work for this combination of applications and species but not guaranteed.
Incompatible
Does not work for this combination of applications and species.
| Application | Species |
|---|---|
| WB |
Human
|
| Application | Abreviews | Notes |
|---|---|---|
| ICC |
Use a concentration of 10 µg/ml.
|
| Notes |
|---|
|
ICC
Use a concentration of 10 µg/ml. |
Target
-
Function
May be involved in the regulation of dopamine release and transport. Induces fibrillization of microtubule-associated protein tau. Reduces neuronal responsiveness to various apoptotic stimuli, leading to a decreased caspase-3 activation. -
Tissue specificity
Expressed principally in brain but is also expressed in low concentrations in all tissues examined except in liver. Concentrated in presynaptic nerve terminals. -
Involvement in disease
Genetic alterations of SNCA resulting in aberrant polymerization into fibrils, are associated with several neurodegenerative diseases (synucleinopathies). SNCA fibrillar aggregates represent the major non A-beta component of Alzheimer disease amyloid plaque, and a major component of Lewy body inclusions. They are also found within Lewy body (LB)-like intraneuronal inclusions, glial inclusions and axonal spheroids in neurodegeneration with brain iron accumulation type 1.
Parkinson disease 1
Parkinson disease 4
Dementia Lewy body -
Sequence similarities
Belongs to the synuclein family. -
Domain
The 'non A-beta component of Alzheimer disease amyloid plaque' domain (NAC domain) is involved in fibrils formation. The middle hydrophobic region forms the core of the filaments. The C-terminus may regulate aggregation and determine the diameter of the filaments. -
Post-translational
modificationsPhosphorylated, predominantly on serine residues. Phosphorylation by CK1 appears to occur on residues distinct from the residue phosphorylated by other kinases. Phosphorylation of Ser-129 is selective and extensive in synucleinopathy lesions. In vitro, phosphorylation at Ser-129 promoted insoluble fibril formation. Phosphorylated on Tyr-125 by a PTK2B-dependent pathway upon osmotic stress.
Hallmark lesions of neurodegenerative synucleinopathies contain alpha-synuclein that is modified by nitration of tyrosine residues and possibly by dityrosine cross-linking to generated stable oligomers.
Ubiquitinated. The predominant conjugate is the diubiquitinated form.
Acetylation at Met-1 seems to be important for proper folding and native oligomeric structure. -
Cellular localization
Cytoplasm, cytosol. Membrane. Nucleus. Cell junction, synapse. Secreted. Membrane-bound in dopaminergic neurons. - Information by UniProt
-
Database links
- Entrez Gene: 6622 Human
- Omim: 163890 Human
- SwissProt: P37840 Human
- Unigene: 21374 Human
-
Alternative names
- Alpha synuclein antibody
- Alpha-synuclein antibody
- Alpha-synuclein, isoform NACP140 antibody
see all
Images
-
Immunocytochemistry - Anti-Alpha-synuclein antibody [syn204] (ab3309)ab3309 staining Alpha-Synuclein in wild-type Hap1 cells (top panel) and SNCA knockout Hap1 cells (bottom panel). The cells were fixed with 4% paraformaldehyde (10 min) then permeabilized with 0.1% Triton X-100 for 5 minutes and then blocked with 1% BSA/10% normal goat serum/0.3M glycine in 0.1% PBS-Tween for 1h. The cells were then incubated with ab3309 at 10μg/ml concentration and ab6046 (Rabbit polyclonal to beta Tubulin) at 1/1000 dilution overnight at 4°C followed by a further incubation at room temperature for 1h with a goat secondary antibody to mouse IgG (Alexa Fluor® 488) (ab150117) at 2 μg/ml (shown in green) and a goat secondary antibody to rabbit IgG (Alexa Fluor® 594) (ab150080) at 2 μg/ml (shown in red). Nuclear DNA was labelled in blue with DAPI.
Image was taken with a confocal microscope (Leica-Microsystems TCS SP8).
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (8)
ab3309 has been referenced in 8 publications.
- Park HJ et al. Ethanol extract from Gynostemma pentaphyllum ameliorates dopaminergic neuronal cell death in transgenic mice expressing mutant A53T human alpha-synuclein. Neural Regen Res 15:361-368 (2020). PubMed: 31552910
- Agerschou ED et al. An engineered monomer binding-protein for a-synuclein efficiently inhibits the proliferation of amyloid fibrils. Elife 8:N/A (2019). PubMed: 31389332
- Nevzglyadova OV et al. Yeast red pigment modifies cloned human a-synuclein pathogenesis in Parkinson disease models in Saccharomyces cerevisiae and Drosophila melanogaster. Neurochem Int 120:172-181 (2018). PubMed: 30099122
- Ma L et al. C-terminal truncation exacerbates the aggregation and cytotoxicity of a-Synuclein: A vicious cycle in Parkinson's disease. Biochim Biophys Acta Mol Basis Dis 1864:3714-3725 (2018). PubMed: 30290273
- Shahnawaz M et al. Development of a Biochemical Diagnosis of Parkinson Disease by Detection of a-Synuclein Misfolded Aggregates in Cerebrospinal Fluid. JAMA Neurol 74:163-172 (2017). PubMed: 27918765
- Bassil F et al. Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy. Proc Natl Acad Sci U S A 113:9593-8 (2016). SDS-PAGE . PubMed: 27482103
- Volpicelli-Daley LA et al. Addition of exogenous a-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous a-synuclein to Lewy body and Lewy neurite-like aggregates. Nat Protoc 9:2135-46 (2014). PubMed: 25122523
- Croisier E et al. Comparative study of commercially available anti-alpha-synuclein antibodies. Neuropathol Appl Neurobiol 32:351-6 (2006). PubMed: 16640654